EIKN (NASDAQ:EIKN) Given Consensus Rating of “Moderate Buy” by Brokerages

EIKN (NASDAQ:EIKN) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $25.60.

Several equities research analysts recently weighed in on the company. Zacks Research raised EIKN to a “hold” rating in a report on Friday, February 27th. Cantor Fitzgerald initiated coverage on shares of EIKN in a report on Monday, March 2nd. They issued an “overweight” rating on the stock. JPMorgan Chase & Co. started coverage on shares of EIKN in a report on Monday, March 2nd. They set an “overweight” rating and a $29.00 price target for the company. Wedbush assumed coverage on EIKN in a research report on Thursday, February 26th. They set an “underperform” rating and a $7.00 target price on the stock. Finally, Wall Street Zen downgraded EIKN from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th.

EIKN Trading Down 4.9%

EIKN opened at $10.53 on Friday. EIKN has a 52 week low of $9.93 and a 52 week high of $17.40.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.